Literature DB >> 17986507

Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?

S Strasser-Fuchs1, C Enzinger, S Ropele, M Wallner, F Fazekas.   

Abstract

Magnetic resonance imaging (MRI) techniques such as magnetization transfer imaging and magnetic resonance spectroscopy (MRS) may reveal otherwise undetectable tissue damage in multiple sclerosis (MS) and can serve to explain more severe disability than expected from conventional MRI. That an inverse situation may exist where non-conventional quantitative MRI and MRS metrics would indicate less abnormality than expected from T2 lesion load to explain preserved clinical functioning was hypothesized. Quantitative MRI and MRS were obtained in 13 consecutive patients with clinically benign MS (BMS; mean age 44 +/- 9 years) despite large T 2 lesion load and in 15 patients with secondary progressive MS (SPMS; mean age 47 +/- 6 years) matched for disease duration. The magnetization transfer ratio (MTR), magnetization transfer rate (kfor), brain parenchymal fraction (BPF) and brain metabolite concentrations from proton MRS were determined. BMS patients were significantly less disabled than their SPMS counterparts (mean expanded disability status score: 2.1 +/- 1.1 versus 6.2 +/- 1.1; P < 0.001) and had an even somewhat higher mean T2 lesion load (41.2 +/- 27.1 versus 27.9 +/- 24.8 cm3; P = 0.19). Normal appearing brain tissue histogram metrics for MTR and kfor, mean MTR and kfor of MS lesions and mean BPF were similar in BMS and SPMS patients. Levels of N-acetyl-aspartate, choline and myoinositol were comparable between groups. This study thus failed to explain the preservation of function in our BMS patients with large T2 lesion load by a higher morphologic or metabolic integrity of the brain parenchyma. Functional compensation must come from other mechanisms such as brain plasticity.

Entities:  

Mesh:

Year:  2007        PMID: 17986507     DOI: 10.1177/1352458507082354

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  13 in total

Review 1.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

2.  Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.

Authors:  Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

3.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.

Authors:  D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen
Journal:  Mult Scler       Date:  2011-09-15       Impact factor: 6.312

4.  Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis.

Authors:  R Zivadinov; B Raj; M Ramanathan; B Teter; J Durfee; M G Dwyer; N Bergsland; C Kolb; D Hojnacki; R H Benedict; B Weinstock-Guttman
Journal:  AJNR Am J Neuroradiol       Date:  2016-02-18       Impact factor: 3.825

5.  Global N-acetylaspartate declines even in benign multiple sclerosis.

Authors:  D J Rigotti; O Gonen; R I Grossman; J S Babb; A Falini; B Benedetti; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-21       Impact factor: 3.825

6.  Multi-task functional MRI in multiple sclerosis patients without clinical disability.

Authors:  René A Colorado; Karan Shukla; Yuxiang Zhou; Jerry S Wolinsky; Ponnada A Narayana
Journal:  Neuroimage       Date:  2011-08-05       Impact factor: 6.556

7.  Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis at 7T.

Authors:  Adrienne N Dula; Siddharama Pawate; Richard D Dortch; Robert L Barry; Kristen M George-Durrett; Bailey D Lyttle; Lindsey M Dethrage; John C Gore; Seth A Smith
Journal:  Mult Scler       Date:  2015-07-24       Impact factor: 6.312

8.  Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.

Authors:  Lutz Achtnichts; Oded Gonen; Daniel J Rigotti; James S Babb; Yvonne Naegelin; Iris-Katharina Penner; Kerstin Bendfeldt; Jochen Hirsch; Michael Amann; Ludwig Kappos; Achim Gass
Journal:  Eur J Radiol       Date:  2013-09-04       Impact factor: 3.528

9.  Corpus callosum damage and cognitive dysfunction in benign MS.

Authors:  Sarlota Mesaros; Maria A Rocca; Gianna Riccitelli; Elisabetta Pagani; Marco Rovaris; Domenico Caputo; Angelo Ghezzi; Ruggero Capra; Antonio Bertolotto; Giancarlo Comi; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2009-08       Impact factor: 5.038

10.  Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: a hint for an early identification of benign MS?

Authors:  Nicolò Margaritella; Laura Mendozzi; Massimo Garegnani; Raffaello Nemni; Elena Colicino; Elisabetta Gilardi; Luigi Pugnetti
Journal:  BMC Neurol       Date:  2012-08-22       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.